Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 11 citing articles:

HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 19
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Ziming Li, Yan Wang, Yuping Sun, et al.
The Lancet Oncology (2025)
Closed Access | Times Cited: 1
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
Junjie Li, Zhihua Wang, Liangan Chen, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
Ding Ma, Lei-Jie Dai, Xiangrong Wu, et al.
Cancer Cell (2025)
Closed Access | Times Cited: 1
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Yu Aoki, Izuma Nakayama, Kohei Shitara
Current Oncology Reports (2025)
Closed Access
Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights from clinical studies
Jiya Jose, John D. Hooper, Fernando Souza-Fonseca-Guimarães
Immunology and Cell Biology (2025)
Closed Access
Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives
Zhenjun Huang, Qing Peng, Luhui Mao, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Antibody-drug conjugates in breast cancer: current evidence and future directions
Ning Li, Lu Yang, Zixuan Zhao, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?
Andri Papakonstantinou, Theodoros Foukakis
Annals of Oncology (2025)
Closed Access
Advances in the Study of Antibody-Drug Conjugates Targeting HER2 for the Treatment of Non-Small Cell Lung Cancer
熙 黄
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 984-991
Closed Access
Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial
Huan Li, Min Yan, Zhaohui Li, et al.
Cancer Science (2025)
Open Access
Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
Jianli Zhao, Yunfang Yu, Wei Ren, et al.
MedComm (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 2
Page 1

Scroll to top